J
James D. Levine
Researcher at Beth Israel Deaconess Medical Center
Publications - 65
Citations - 2886
James D. Levine is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: T cell & Dendritic cell. The author has an hindex of 21, co-authored 65 publications receiving 2657 citations. Previous affiliations of James D. Levine include Harvard University.
Papers
More filters
Journal ArticleDOI
Functional isolation and characterization of human hematopoietic stem cells.
TL;DR: Human bone marrow cells that were responsive to the early-acting cytokines Kit ligand and interleukin-3 were forced to a metabolic death and the subfraction remaining represented 1 in 10 bone marrow mononuclear cells were determined to be quiescent by cell cycle analysis, and had a stem cell immunophenotype.
Journal ArticleDOI
Recombinant human erythropoietin for patients with AIDS treated with zidovudine.
Margaret A. Fischl,Jeffrey E. Galpin,James D. Levine,Jerome E. Groopman,David H. Henry,Peter Kennedy,Steven A. Miles,William J. Robbins,Barbara Starrett,Ralph Zalusky,Robert I. Abels,Huei C. Tsai,Seth A. Rudnick +12 more
TL;DR: It is concluded that recombinant human erythropoietin may be useful in patients with AIDS treated with zidovudine, although the indicators for its use remain to be clarified.
Journal ArticleDOI
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt,Brett Glotzbecker,Heidi Mills,Baldev Vasir,Dimitrios Tzachanis,James D. Levine,Robin Joyce,Kerry Wellenstein,Whitney Keefe,Michael Schickler,Rinat Rotem-Yehudar,Donald Kufe,David Avigan +12 more
TL;DR: It is demonstrated that PD-1 expression is increased in T cells of patients with active myeloma, and that CT-011 enhances activated T-cell responses after DC/tumor fusion stimulation.
Journal ArticleDOI
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
Jacalyn Rosenblatt,Baldev Vasir,Lynne Uhl,Simona Blotta,Claire MacNamara,Poorvi Somaiya,Zekui Wu,Robin Joyce,James D. Levine,Dilani Dombagoda,Yan Emily Yuan,Karen Francoeur,Donna Fitzgerald,Paul G. Richardson,Edie Weller,Kenneth C. Anderson,Donald Kufe,Nikhil C. Munshi,David Avigan +18 more
TL;DR: Vaccination with DC/multiple myeloma fusions was feasible and well tolerated and resulted in antitumor immune responses and disease stabilization in a majority of patients.
Journal ArticleDOI
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Robert J. Soiffer,Haesook T. Kim,Joseph P. McGuirk,Mitchell E. Horwitz,Laura Johnston,Mrinal M. Patnaik,Witold B. Rybka,Andrew S. Artz,David L. Porter,Thomas C. Shea,Michael Boyer,Richard T. Maziarz,Paul J. Shaughnessy,Usama Gergis,Hana Safah,Ran Reshef,John F. DiPersio,Patrick J. Stiff,Madhuri Vusirikala,Jeff Szer,Jennifer Holter,James D. Levine,Paul J. Martin,Joseph Pidala,Ian D. Lewis,Vincent T. Ho,Edwin P. Alyea,Jerome Ritz,Frank Glavin,Peter Westervelt,Madan Jagasia,Yi Bin Chen +31 more
TL;DR: A prospective, double-blind phase III trial to investigate the effect of ATLG on cGVHD-free survival found that in vivo T-cell depletion with anti-T-lymphocyte globulin reduces chronic graft-versus-host disease (cGVHD) without compromising survival.